Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2016 - 2025)

Syndax Pharmaceuticals has reported Total Non-Current Liabilities over the past 11 years, most recently at $345.0 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $345.0 million for Q4 2025, up 3.55% from a year ago — trailing twelve months through Dec 2025 was $345.0 million (up 3.55% YoY), and the annual figure for FY2025 was $345.0 million, up 3.55%.
  • Total Non-Current Liabilities for Q4 2025 was $345.0 million at Syndax Pharmaceuticals, up from $322.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for SNDX hit a ceiling of $345.0 million in Q4 2025 and a floor of $2000.0 in Q3 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $12.7 million (2021), compared with a mean of $88.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 99.77% in 2024 and later skyrocketed 16108650.0% in 2025.
  • Syndax Pharmaceuticals' Total Non-Current Liabilities stood at $20.6 million in 2021, then crashed by 96.5% to $722000.0 in 2022, then dropped by 18.56% to $588000.0 in 2023, then surged by 56556.97% to $333.1 million in 2024, then rose by 3.55% to $345.0 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $345.0 million (Q4 2025), $322.2 million (Q3 2025), and $325.7 million (Q2 2025) per Business Quant data.